These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 26170630

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ, Seib CD, Gosnell J.
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.
    J Clin Oncol; 2010 Feb 10; 28(5):767-72. PubMed ID: 20065189
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.
    J Clin Endocrinol Metab; 2010 Jun 10; 95(6):2664-71. PubMed ID: 20371662
    [Abstract] [Full Text] [Related]

  • 13. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN, Banaszynski ME, Kolesar JM.
    Am J Health Syst Pharm; 2013 May 15; 70(10):849-55. PubMed ID: 23640345
    [Abstract] [Full Text] [Related]

  • 14. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.
    Thyroid; 2015 Apr 15; 25(4):386-91. PubMed ID: 25627619
    [Abstract] [Full Text] [Related]

  • 15. Vandetanib: in medullary thyroid cancer.
    Frampton JE.
    Drugs; 2012 Jul 09; 72(10):1423-36. PubMed ID: 22715896
    [Abstract] [Full Text] [Related]

  • 16. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH, Robinson BG, Learoyd DL.
    Expert Opin Drug Saf; 2016 Aug 09; 15(8):1107-13. PubMed ID: 27301016
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, Gramza AW.
    Oncologist; 2019 Jan 09; 24(1):16-e14. PubMed ID: 30297385
    [Abstract] [Full Text] [Related]

  • 18. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M, Yoon JH, Ahn J, Jeon MJ, Kim HK, Lim DJ, Kang HC, Kim IJ, Shong YK, Kim TY, Kim BH.
    Endocrinol Metab (Seoul); 2020 Sep 09; 35(3):587-594. PubMed ID: 32981301
    [Abstract] [Full Text] [Related]

  • 19. Novel therapies for thyroid cancer.
    Krajewska J, Jarzab B.
    Expert Opin Pharmacother; 2014 Dec 09; 15(18):2641-52. PubMed ID: 25318585
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.